Safety and efficacy of the ThermoCool SmartTouch SurroundFlow catheter for atrial fibrillation ablation: A meta-analysis.

16 In an additional prospective trial by Maurer et al, it was shown that 79.7% of patients from the STSFc group were free from AF (74.3% in the STc group) after a mean follow‐up of 12 ± 3 months, even though the result did not reach statistical significance ( P = .18), there was a trend towards improved efficacy of the STSFc when compared to STc. 18 Additionally, the Ablation Index (AI), which represents a new lesion quality marker, has been shown to allow acute durable PVI followed by increased long‐term success. 27 , 28 Solimene et al made a prospective, multicenter study and compared STSFc with STc for AF ablation that was guided by different AI settings.

also in 111,027 other papers